Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jun;28(6):715–723. doi: 10.1111/j.1464-5491.2011.03276.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Journal compilation © 2011 Diabetes UK

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

PMC Copyright notice

Overall treatment satisfaction, as measured by the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs), in patients initially receiving liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks, and then receiving liraglutide 1.8 mg once daily for 14 weeks (patient-reported outcome analysis population with data in extension phase of trial). *Comparison of liraglutide vs. exenatide change from baseline. †Comparison of week 40 vs. week 26 in the exenatide to liraglutide group.